Market Overview

UPDATE: ISI Group Cuts PT to $39 on Charles River Laboratories Following Negative Guidance

Related CRL
Charles River Laboratories, AstraZeneca Renew Strategic Partnership Agreement
Benzinga's Top Downgrades

ISI Group reiterated its Underweight rating on Charles River Laboratories (NYSE: CRL) and lowered its price target from $40.50 to $39.

ISI Group commented, "As a result of today's 2013 guidance announcement, we are lowering CRL's FY13 EPS from $3.10 to $3.00 and FY14 EPS from $3.45 to $3.25. These EPS changes stem from lower operating margin expectations due to the aforementioned investment headwinds. Despite the improved revenue outlook, limited visibility across the business (ex strategic deals) and a challenged OM outlook will limit P/E expansion, and in turn, cap shares in the upper $30s."

Charles River Laboratories closed at $36.55 on Tuesday.

Latest Ratings for CRL

Aug 2015Credit SuisseAssumesNeutral
Jul 2015CitigroupMaintainsNeutral
Jul 2015BarclaysDowngradesEqual-weightUnderweight

View More Analyst Ratings for CRL
View the Latest Analyst Ratings

Posted-In: ISI GroupAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (CRL)

View Comments and Join the Discussion!

Get Benzinga's Newsletters